ClinicalTrials.gg
CompletedNCT04522102Updated Mar 26, 2025

Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral HaemorrhaGe (ASPIRING)-Pilot Phase

A Phase 3 interventional study of Start antiplatelet monotherapy in Intracerebral Hemorrhage, sponsored by The George Institute for Global Health, China. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by The George Institute for Global Health, China · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 123 studies in Cerebral Hemorrhage with a site in China — 59 open to participants now, 62 under way, 5 of them phase 3. Cerebral Hemorrhage · China.

Enrollment
58th of 77
80 · median 180
Started
2021
with 12 others
Phase 3
11 of 123
4 open now
Registered
37th of 123
by date

Among the 123 studies in Cerebral Hemorrhage with a site in China, this one is the 58th largest by enrollment of the 77 interventional ones that give a count, is one of 13 that started in 2021, is one of 11 in phase 3, and was the 37th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

59 of the 123 studies in Cerebral Hemorrhage with a site in China are open now. Recruiting first, the newest first:

54 more — sign in →

All 59 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Cerebral Hemorrhage with a site in China, or all of them as a file.
02

Study summary

ASPIRING is an investigator-led, multicentre, prospective, randomised, open-label, blind outcome (PROBE), parallel group, clinical trial. The pilot phase will explore the feasibility of conducting a trial of starting antiplatelet monotherapy versus avoiding antiplatelet therapy for reducing all serious vascular events for adults surviving symptomatic stroke due to spontaneous intracerebral haemorrhage (ICH). The pilot phase will involve \~120 patients at \~30 hospitals in China, Australia and New Zealand.

Read the detailed description

The participant eligibility criteria specifically identify adults with history of symptomatic spontaneous ICH. Randomisation occurs if a participant and their doctor are uncertain about whether to start or avoid antiplatelet monotherapy at least 24 hours after ICH symptom onset. The intervention is a pragmatic policy of starting antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation). The control group adopts a policy of avoiding antiplatelet therapy.

03

Conditions studied

  • Intracerebral Hemorrhage

Keywords

  • stroke
  • intracerebral hemorrhage
  • antiplatelet therapy
  • aspirin
  • clopidogrel
  • cilostazol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient age ≥18 years.
  2. Symptomatic stroke due to spontaneous (non-traumatic) ICH.
  3. Patient is at least 24 hours after ICH symptom onset.
  4. Patient and their doctor are both uncertain about whether to start or avoid antiplatelet monotherapy.
  5. Consent to randomisation from the patient (or personal / legal / professional representative if the patient does not have mental capacity).

Exclusion criteria

Exclusion Criteria:

  1. ICH due to head injury, in the opinion of the investigator.
  2. ICH due to haemorrhagic transformation of an ischaemic stroke, in the opinion of the investigator.
  3. Patient is already taking antiplatelet therapy, or full dose anticoagulant therapy, after ICH.
  4. Patient is pregnant, breastfeeding, or of childbearing age and not taking .
  5. Patient and carer unable to understand spoken or written local language.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Intervention

    Start antiplatelet monotherapy (one antiplatelet drug available in local standard clinical practice, chosen by patient's physician pre-randomisation).

    Drug: Start antiplatelet monotherapy

  • No intervention
    Comparator

    Avoid antiplatelet therapy.

Interventions

  • DrugStart antiplatelet monotherapy

    Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation

06

What researchers measure

Primary outcomes

  1. regulatory approvals

    Receipt of regulatory approvals in China,Australia and New Zealand separately, including Ethics, Human Genetics Resources Administration of China (HGRAC).

    Time frame: 6 months

Secondary outcomes

  1. trial database

    Trial database structure and data flows that comply with data privacy and information governance regulations in China, Australia and New Zealand.

    Time frame: 6 months

  2. Site recruitment

    Participation of 20 sites in China and 10 sites in Australia and New Zealand

    Time frame: 12-18 month

  3. Calculate frequency of clinical data

    Frequency of ICH survivors who are screened, eligible, approached, consented, and randomised by month and site from activation.

    Time frame: 3 years

  4. Barriers to randomisation of eligible patients.

    Barriers to randomisation of eligible patients.

    Time frame: 3 years

  5. Frequency of protocol deviations and violations.

    Frequency of protocol deviations and violations.

    Time frame: 3 years

  6. Adherence to the allocated intervention by investigators and participants

    Adherence to the allocated intervention by investigators and participants

    Time frame: 3 years

  7. Frequency of withdrawal and loss to follow-up

    Frequency of withdrawal and loss to follow-up

    Time frame: 3 years

  8. Completeness of follow-up assessments

    Completeness of follow-up assessments

    Time frame: 3 years

  9. Characteristics of randomised participants compared with eligible patients who were not recruited.

    Characteristics of randomised participants compared with eligible patients who were not recruited.

    Time frame: 3 years

  10. Frequency of the composite of all serious vascular events

    composite of all serious vascular events (non-fatal stroke, non-fatal myocardial infarction or death from a vascular cause)

    Time frame: 6 months

  11. Serious adverse event (SAE)

    any serious adverse event (SAE)

    Time frame: at least 6 months

  12. Serious adverse reaction (SAR)

    serious adverse reaction (SAR)

    Time frame: at least 6 months

  13. Suspected Unexpected Serious Adverse Reaction (SUSAR)

    Suspected Unexpected Serious Adverse Reaction (SUSAR)

    Time frame: at least 6 months

07

Study locations

2 sites
  • The George Institute for Global Health
    Beijing, Beijing 100088, China
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai 200000, China
08

References and documents

Publications

  • Li L, Poon MTC, Samarasekera NE, Perry LA, Moullaali TJ, Rodrigues MA, Loan JJM, Stephen J, Lerpiniere C, Tuna MA, Gutnikov SA, Kuker W, Silver LE, Al-Shahi Salman R, Rothwell PM. Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies. Lancet Neurol. 2021 Jun;20(6):437-447. doi: 10.1016/S1474-4422(21)00075-2. PubMed 34022170 ↗
  • Cheng X, Dong Q. Towards individualised secondary prevention after intracerebral haemorrhage. Lancet Neurol. 2021 Jun;20(6):411-413. doi: 10.1016/S1474-4422(21)00130-7. No abstract available. PubMed 34022160 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Oct 2023, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 21, 2020
StartActual
Sep 3, 2021
Primary completionActual
Oct 13, 2023
CompletionActual
Oct 13, 2023
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04522102
Lead sponsor
The George Institute for Global Health, China
Collaborators
University of Edinburgh, Huashan Hospital, The University of Western Australia
Responsible party
Sponsor
First posted
Aug 21, 2020
Start date
Sep 3, 2021
Primary completion
Oct 13, 2023
Completion
Oct 13, 2023
Last update
Mar 26, 2025

Study contacts

Rustam Al-Shahi Salman
principal investigator · University of Edinburgh
Craig S Anderson
principal investigator · The George Institute
Graeme Hankey, MD
principal investigator · The University of Western Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion